Onglyza Heart Failure and Cancer Risk
AstraZeneca was deeply involved in a study known as the Savor study. During the Savor study, Onglyza (Saxagliptin) was produced. According to the Savor study, an FDA Advisory Council suggested modifying the label. The new labels will be having information regarding the risk of heart failure and death. Patients who are diagnosed with type 2 diabetes and are prescribed to take Onglyza, have a higher risk of types of cardiovascular complications, pancreatitis, pancreatic cancer, or thyroid cancer.
FDA Onglyza Warnings
Onglyza and another type 2 diabetic medicine received a warning in 2013 by FDA regarding the risk of pancreatitis and pancreatic cancer. After this, FDA came to terms for Onglyza to warn patients with the high risk of heart failure. This change was brought after clinical trials where Onglyza was responsible for 27% increased risk of heart failure.